Characteristics | No.(%) | Characteristics | No.(%) |
---|---|---|---|
Clinical stage | Â | Grade | Â |
   II B | 32 (26.9%) |    I | 1 (0.8%) |
   III A | 56 (47.1%) |    II | 67 (56.3%) |
   III B | 22 (18.5%) |    III | 15 (12.6%) |
   III C | 9 (7.5%) |    Not graded | 36 (30.3%) |
Pre-cALN | Â | Post-cALN | Â |
   negative | 36 (30.3%) |    negative | 81 (68.1%) |
   positive | 83 (69.7%) |    positive | 38 (31.9%) |
Pre-ER |  | Post-ER※ |  |
   negative | 58 (48.7%) |    negative | 82 (75.2%) |
   positive | 61 (51.3%) |    positive | 27 (24.8%) |
Pre-PR |  | Post-PR※ |  |
   negative | 60 (50.4%) |    negative | 84 (77.1%) |
   positive | 59 (49.6%) |    positive | 25 (22.9%) |
Pre-HER-2 |  | Post-HER-2※ |  |
   0-2+ | 86 (72.3%) |    0-2+ | 79 (72.5%) |
   3+ | 33 (27.7%) |    3+ | 30 (27.5%) |
Pre-Ki67 |  | Post-Ki67※ |  |
   ≤ 20% | 74 (62.2%) |    ≤ 20% | 93 (85.3%) |
   >20% | 45 (37.8%) |    >20% | 16 (14.7%) |
Pathology | Â | Pathological tumor size | Â |
   IDC | 92 (77.3%) |    ≤ 2 cm | 28 (23.5%) |
   ILC | 4 (3.4%) |    > 2 cm | 59 (49.6%) |
   other | 23 (19.3%) |    unmeasured | 32 (26.9%) |
Clinical response | Â | pALN | Â |
   CR | 27 (22.7%) |    N 0 | 39 (32.8%) |
   PR | 78 (65.6%) |    N 1-3 | 24 (20.2%) |
   SD | 13 (10.9%) |    N 4-9 | 35 (29.4%) |
   PD | 1 (0.8%) |    N >9 | 21 (17.6%) |
Pathological response in tumor site | Â | Â | Â |
   T-A | 22 (18.5%) |  |  |
   T-B | 75 (63.0%) |  |  |
   T-C | 22 (18.5%) |  |  |